Antimicrobial prophylaxis and the prevention of surgical site infection in cardiac surgery: an analysis of 21 007 patients in Switzerland†.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
01 Oct 2019
Historique:
received: 08 10 2018
revised: 14 01 2019
accepted: 15 01 2019
pubmed: 24 2 2019
medline: 28 10 2020
entrez: 24 2 2019
Statut: ppublish

Résumé

Our goal was to determine the optimal timing and choice of surgical antimicrobial prophylaxis (SAP) in patients having cardiac surgery. The setting was the Swiss surgical site infection (SSI) national surveillance system with a follow-up rate of >94%. Participants were patients from 14 hospitals who had cardiac surgery from 2009 to 2017 with clean wounds, SAP with cefuroxime, cefazolin or a vancomycin/cefuroxime combination and timing of SAP within 120 min before the incision. Exposures were SAP timing and agents; the main outcome was the incidence of SSI. We fitted generalized additive and mixed-effects generalized linear models to describe effects predicting SSIs. A total of 21 007 patients were enrolled with an SSI incidence of 5.5%. Administration of SAP within 30 min before the incision was significantly associated with decreased deep/organ space SSI [adjusted odds ratio (OR) 0.73, 95% confidence interval (CI) 0.54-0.98; P = 0.035] compared to administration of SAP 60-120 min before the incision. Cefazolin (adjusted OR 0.64, 95% CI 0.49-0.84; P = 0.001) but not vancomycin/cefuroxime combination (adjusted OR 1.05, 95% CI 0.82-1.34; P = 0.689) was significantly associated with a lower risk of overall SSI compared to cefuroxime alone. Nevertheless, there were no statistically significant differences between the SAP agents and the risk of deep/organ space SSI. The results from this large prospective study provide substantial arguments that administration of SAP close to the time of the incision is more effective than earlier administration before cardiac surgery, making compliance with SAP administration easier. The choice of SAP appears to play a significant role in the prevention of all SSIs, even after adjusting for confounding variables.

Identifiants

pubmed: 30796448
pii: 5363248
doi: 10.1093/ejcts/ezz039
doi:

Substances chimiques

Anti-Bacterial Agents 0
Drug Combinations 0
Vancomycin 6Q205EH1VU
Cefuroxime O1R9FJ93ED

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

800-806

Investigateurs

Carlo Balmelli (C)
Marie-Christine Eisenring (MC)
Stephan Harbarth (S)
Stefan P Kuster (SP)
Jonas Marschall (J)
Virginie Masserey Spicher (VM)
Didier Pittet (D)
Christian Ruef (C)
Hugo Sax (H)
Matthias Schlegel (M)
Alexander Schweiger (A)
Nicolas Troillet (N)
Andreas F Widmer (AF)
Giorgio Zanetti (G)

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Rami Sommerstein (R)

Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.

Andrew Atkinson (A)

Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.

Stefan P Kuster (SP)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Swissnoso, the National Center for Infection Control, Bern, Switzerland.

Maurus Thurneysen (M)

Department of Infectious Diseases, University Hospital Basel, Basel, Switzerland.

Michele Genoni (M)

Department of Cardiac Surgery, University Hospital of Zurich, Zurich, Switzerland.

Nicolas Troillet (N)

Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Service of Infectious Diseases, Central Institute, Valais Hospitals, Sion, Switzerland.

Jonas Marschall (J)

Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Swissnoso, the National Center for Infection Control, Bern, Switzerland.

Andreas F Widmer (AF)

Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Department of Infectious Diseases, University Hospital Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH